Liver transplant recipients (n = 61) showed improved humoral immune response after a third BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (P < 0.0001). The activated T cell counts and the levels of anti-RBD IgG and neutralizing antibodies were increased after the third dose (P = 0.008, P < 0.0001 and P < 0.0001, respectively). Adverse effects, reported by 37% of recipients, were mild.
References
Original article
Davidov, Y. et al. A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients. J. Hepatol. https://doi.org/10.1016/j.jhep.2022.03.042 (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kotsiliti, E. Anti-SARS-CoV-2 vaccine in liver transplantation. Nat Rev Gastroenterol Hepatol 19, 350 (2022). https://doi.org/10.1038/s41575-022-00624-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-022-00624-8
